Traws Pharma, Inc.
TRAW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $226 | $226 | $226 | $226 |
| % Growth | 0% | 0% | 0% | – |
| Cost of Goods Sold | $12 | $0 | $0 | $0 |
| Gross Profit | $214 | $226 | $226 | $226 |
| % Margin | 94.7% | 100% | 100% | 100% |
| R&D Expenses | $130,311 | $11,430 | $11,406 | $7,297 |
| G&A Expenses | $12,289 | $9,094 | $8,447 | $9,425 |
| SG&A Expenses | $12,289 | $9,094 | $8,447 | $9,425 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$93,038 | $0 | $0 | $0 |
| Operating Expenses | $49,562 | $20,524 | $19,853 | $16,722 |
| Operating Income | -$49,348 | -$20,298 | -$19,627 | -$16,496 |
| % Margin | -21,835.4% | -8,981.4% | -8,684.5% | -7,299.1% |
| Other Income/Exp. Net | -$117,175 | $1,350 | $663 | $333 |
| Pre-Tax Income | -$166,523 | -$18,948 | -$18,964 | -$16,163 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$54,674 | -$18,948 | -$18,964 | -$16,163 |
| % Margin | -24,192% | -8,384.1% | -8,391.2% | -7,151.8% |
| EPS | -35.21 | -22.569 | -22.675 | -24.006 |
| % Growth | -56% | 0.5% | 5.5% | – |
| EPS Diluted | -35.21 | -22.569 | -22.675 | -24.006 |
| Weighted Avg Shares Out | 1,553 | 840 | 836 | 673 |
| Weighted Avg Shares Out Dil | 1,553 | 840 | 836 | 673 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $12 | $16 | $14 | $14 |
| EBITDA | -$166,511 | -$20,282 | -$19,613 | -$16,482 |
| % Margin | -73,677.4% | -8,974.3% | -8,678.3% | -7,292.9% |